Selected research
Market Structure
Global New Drug Modeling Solution Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global New Drug Modeling Solution market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for New Drug Modeling Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for New Drug Modeling Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for New Drug Modeling Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for New Drug Modeling Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of New Drug Modeling Solution include JSR Corporation(Crown Bioscience), Chemical Computing Group ULC, Nimbus Therapeutics, schrodinger, Inc, Genedata AG, Biognos AB, Compugen Ltd, Dassault Systemes and Acellera, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global New Drug Modeling Solution market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of New Drug Modeling Solution and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents New Drug Modeling Solution revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the New Drug Modeling Solution market size, projected growth trends, production technologies, key applications, and end-use industries.
New Drug Modeling Solution Segment by Company
JSR Corporation(Crown Bioscience)
Chemical Computing Group ULC
Nimbus Therapeutics
schrodinger, Inc
Genedata AG
Biognos AB
Compugen Ltd
Dassault Systemes
Acellera
lnstem(Leadscope)
New Drug Modeling Solution Segment by Type
Database
Software
Others
New Drug Modeling Solution Segment by Application
Drug Discovery and Development
Computational Physiological Medicine
Disease Modeling
Others
New Drug Modeling Solution Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global New Drug Modeling Solution market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of New Drug Modeling Solution and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of New Drug Modeling Solution.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of New Drug Modeling Solution in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global New Drug Modeling Solution industry.
Chapter 3: Detailed analysis of New Drug Modeling Solution companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, New Drug Modeling Solutionrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Database
- Software
- Others
Applications
- Drug Discovery and Development
- Computational Physiological Medicine
- Disease Modeling
- Others
Companies covered
- JSR Corporation(Crown Bioscience)
- Chemical Computing Group ULC
- Nimbus Therapeutics
- schrodinger, Inc
- Genedata AG
- Biognos AB
- Compugen Ltd
- Dassault Systemes
- Acellera
- lnstem(Leadscope)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global New Drug Modeling Solution Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Database
- 1.2.3 Software
- 1.2.4 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global New Drug Modeling Solution Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Drug Discovery and Development
- 1.3.3 Computational Physiological Medicine
- 1.3.4 Disease Modeling
- 1.3.5 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global New Drug Modeling Solution Growth Trends by Region
- 1.5.1 Global New Drug Modeling Solution Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 New Drug Modeling Solution Market Size by Region (2021-2026)
- 1.5.3 New Drug Modeling Solution Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global New Drug Modeling Solution Market Dynamics
- 2.1 New Drug Modeling Solution Industry Trends
- 2.2 New Drug Modeling Solution Industry Drivers
- 2.3 New Drug Modeling Solution Industry Opportunities and Challenges
- 2.4 New Drug Modeling Solution Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global New Drug Modeling Solution Revenue by Company (2021-2026)
- 3.2 Global New Drug Modeling Solution Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global New Drug Modeling Solution Key Company Head office and Area Served
- 3.4 Global New Drug Modeling Solution Company, Product Type & Application
- 3.5 Global New Drug Modeling Solution Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global New Drug Modeling Solution Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 New Drug Modeling Solution Players Market Share by Revenue in 2025
- 3.6.3 2025 New Drug Modeling Solution Tier 1, Tier 2, and Tier 3
4 New Drug Modeling Solution Market by Type
- 4.1 Global New Drug Modeling Solution Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global New Drug Modeling Solution Market Size by Type (2021-2032)
- 4.3 Global New Drug Modeling Solution Market Size Share by Type (2021-2032)
5 New Drug Modeling Solution Market by Application
- 5.1 Global New Drug Modeling Solution Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global New Drug Modeling Solution Market Size by Application (2021-2032)
- 5.3 Global New Drug Modeling Solution Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 JSR Corporation(Crown Bioscience)
- 6.1.1 JSR Corporation(Crown Bioscience) Company Information
- 6.1.2 JSR Corporation(Crown Bioscience) Business Overview
- 6.1.3 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Product Portfolio
- 6.1.5 JSR Corporation(Crown Bioscience) Recent Developments
- 6.2 Chemical Computing Group ULC
- 6.2.1 Chemical Computing Group ULC Company Information
- 6.2.2 Chemical Computing Group ULC Business Overview
- 6.2.3 Chemical Computing Group ULC New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Chemical Computing Group ULC New Drug Modeling Solution Product Portfolio
- 6.2.5 Chemical Computing Group ULC Recent Developments
- 6.3 Nimbus Therapeutics
- 6.3.1 Nimbus Therapeutics Company Information
- 6.3.2 Nimbus Therapeutics Business Overview
- 6.3.3 Nimbus Therapeutics New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Nimbus Therapeutics New Drug Modeling Solution Product Portfolio
- 6.3.5 Nimbus Therapeutics Recent Developments
- 6.4 schrodinger, Inc
- 6.4.1 schrodinger, Inc Company Information
- 6.4.2 schrodinger, Inc Business Overview
- 6.4.3 schrodinger, Inc New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 schrodinger, Inc New Drug Modeling Solution Product Portfolio
- 6.4.5 schrodinger, Inc Recent Developments
- 6.5 Genedata AG
- 6.5.1 Genedata AG Company Information
- 6.5.2 Genedata AG Business Overview
- 6.5.3 Genedata AG New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Genedata AG New Drug Modeling Solution Product Portfolio
- 6.5.5 Genedata AG Recent Developments
- 6.6 Biognos AB
- 6.6.1 Biognos AB Company Information
- 6.6.2 Biognos AB Business Overview
- 6.6.3 Biognos AB New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Biognos AB New Drug Modeling Solution Product Portfolio
- 6.6.5 Biognos AB Recent Developments
- 6.7 Compugen Ltd
- 6.7.1 Compugen Ltd Company Information
- 6.7.2 Compugen Ltd Business Overview
- 6.7.3 Compugen Ltd New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Compugen Ltd New Drug Modeling Solution Product Portfolio
- 6.7.5 Compugen Ltd Recent Developments
- 6.8 Dassault Systemes
- 6.8.1 Dassault Systemes Company Information
- 6.8.2 Dassault Systemes Business Overview
- 6.8.3 Dassault Systemes New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Dassault Systemes New Drug Modeling Solution Product Portfolio
- 6.8.5 Dassault Systemes Recent Developments
- 6.9 Acellera
- 6.9.1 Acellera Company Information
- 6.9.2 Acellera Business Overview
- 6.9.3 Acellera New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Acellera New Drug Modeling Solution Product Portfolio
- 6.9.5 Acellera Recent Developments
- 6.10 lnstem(Leadscope)
- 6.10.1 lnstem(Leadscope) Company Information
- 6.10.2 lnstem(Leadscope) Business Overview
- 6.10.3 lnstem(Leadscope) New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 lnstem(Leadscope) New Drug Modeling Solution Product Portfolio
- 6.10.5 lnstem(Leadscope) Recent Developments
7 North America
- 7.1 North America New Drug Modeling Solution Market Size (2021-2032)
- 7.2 North America New Drug Modeling Solution Market Size by Type
- 7.2.1 North America New Drug Modeling Solution Market Size by Type (2021-2026)
- 7.2.2 North America New Drug Modeling Solution Market Size by Type (2027-2032)
- 7.2.3 North America New Drug Modeling Solution Market Share by Type (2021-2032)
- 7.3 North America New Drug Modeling Solution Market Size by Application
- 7.3.1 North America New Drug Modeling Solution Market Size by Application (2021-2026)
- 7.3.2 North America New Drug Modeling Solution Market Size by Application (2027-2032)
- 7.3.3 North America New Drug Modeling Solution Market Share by Application (2021-2032)
- 7.4 North America New Drug Modeling Solution Market Size by Country
- 7.4.1 North America New Drug Modeling Solution Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America New Drug Modeling Solution Market Size by Country (2021-2026)
- 7.4.3 North America New Drug Modeling Solution Market Size by Country (2027-2032)
- 7.4.4 North America New Drug Modeling Solution Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe New Drug Modeling Solution Market Size (2021-2032)
- 8.2 Europe New Drug Modeling Solution Market Size by Type
- 8.2.1 Europe New Drug Modeling Solution Market Size by Type (2021-2026)
- 8.2.2 Europe New Drug Modeling Solution Market Size by Type (2027-2032)
- 8.2.3 Europe New Drug Modeling Solution Market Share by Type (2021-2032)
- 8.3 Europe New Drug Modeling Solution Market Size by Application
- 8.3.1 Europe New Drug Modeling Solution Market Size by Application (2021-2026)
- 8.3.2 Europe New Drug Modeling Solution Market Size by Application (2027-2032)
- 8.3.3 Europe New Drug Modeling Solution Market Share by Application (2021-2032)
- 8.4 Europe New Drug Modeling Solution Market Size by Country
- 8.4.1 Europe New Drug Modeling Solution Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe New Drug Modeling Solution Market Size by Country (2021-2026)
- 8.4.3 Europe New Drug Modeling Solution Market Size by Country (2027-2032)
- 8.4.4 Europe New Drug Modeling Solution Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China New Drug Modeling Solution Market Size (2021-2032)
- 9.2 China New Drug Modeling Solution Market Size by Type
- 9.2.1 China New Drug Modeling Solution Market Size by Type (2021-2026)
- 9.2.2 China New Drug Modeling Solution Market Size by Type (2027-2032)
- 9.2.3 China New Drug Modeling Solution Market Share by Type (2021-2032)
- 9.3 China New Drug Modeling Solution Market Size by Application
- 9.3.1 China New Drug Modeling Solution Market Size by Application (2021-2026)
- 9.3.2 China New Drug Modeling Solution Market Size by Application (2027-2032)
- 9.3.3 China New Drug Modeling Solution Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia New Drug Modeling Solution Market Size (2021-2032)
- 10.2 Asia New Drug Modeling Solution Market Size by Type
- 10.2.1 Asia New Drug Modeling Solution Market Size by Type (2021-2026)
- 10.2.2 Asia New Drug Modeling Solution Market Size by Type (2027-2032)
- 10.2.3 Asia New Drug Modeling Solution Market Share by Type (2021-2032)
- 10.3 Asia New Drug Modeling Solution Market Size by Application
- 10.3.1 Asia New Drug Modeling Solution Market Size by Application (2021-2026)
- 10.3.2 Asia New Drug Modeling Solution Market Size by Application (2027-2032)
- 10.3.3 Asia New Drug Modeling Solution Market Share by Application (2021-2032)
- 10.4 Asia New Drug Modeling Solution Market Size by Country
- 10.4.1 Asia New Drug Modeling Solution Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia New Drug Modeling Solution Market Size by Country (2021-2026)
- 10.4.3 Asia New Drug Modeling Solution Market Size by Country (2027-2032)
- 10.4.4 Asia New Drug Modeling Solution Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa New Drug Modeling Solution Market Size (2021-2032)
- 11.2 South America, Middle East & Africa New Drug Modeling Solution Market Size by Type
- 11.2.1 South America, Middle East & Africa New Drug Modeling Solution Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa New Drug Modeling Solution Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa New Drug Modeling Solution Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa New Drug Modeling Solution Market Size by Application
- 11.3.1 South America, Middle East & Africa New Drug Modeling Solution Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa New Drug Modeling Solution Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa New Drug Modeling Solution Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa New Drug Modeling Solution Market Size by Country
- 11.4.1 South America, Middle East & Africa New Drug Modeling Solution Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa New Drug Modeling Solution Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa New Drug Modeling Solution Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa New Drug Modeling Solution Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst